Company profile
UK company 10563794, incorporated on 13 January 2017.
Personalised treatment for immune-mediated diseases | PredictImmune
Our technology is the result of over 15 years research and guides personalised treatment of patients with immune-mediated diseases
Company number 10563794
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
PredictImmune develops prognostic tests immune-mediated diseases, conditions for which a specific cause is currently unknown, such as IBS.
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn's disease and ulcerative colitis). The test, based on a simple whole-blood quantitative PCR assay, predicts long-term disease outcome at diagnosis prior to treatment, stratifying patients into those likely to follow either a quiescent or frequently relapsing course and informing clinical management.
Too early.
1 Nov 2018 to 31 Oct 2019
"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce al...
